Leukemia

Nicole Schulz was 14 when she received an AML diagnosis. She shares what carried her through two transplants and 11 months in the hospital.

FDA approved Cavhanza, a new nilotinib formulation for adults with Ph+ CML that may offer more flexible dosing and easier administration.

FDA approves oral Inqovi plus Venclexta for newly diagnosed AML in older adults or those with comorbidities, expanding non-intensive options.

A leukemia survivor shares how her experience inspired a national support network for young adults navigating cancer and survivorship.

My smile today is one of compassion. It’s a smile that welcomes the stranger I meet. It radiates joy and presence.

Amanda shares advice on resilience, self-advocacy and finding strength while navigating cancer survivorship and chronic GVHD.

Experts highlight rising cancer rates in younger adults and the need for tailored support, treatment and survivorship care across the continuum.

Amanda discusses the hidden challenges of chronic GVHD and how advocacy and storytelling help her support others facing similar struggles.

Amanda shares how a sudden leukemia diagnosis led to a life-saving transplant and the ongoing challenges of chronic graft-versus-host disease.

Though I don’t understand why I’m suffering, I try to hold onto my faith and believe that God is somehow still working in me.

Learn about stage 2 chronic myeloid leukemia, treatment options, side effects, and key questions to guide conversations with your oncologist.

FDA approves Calquence with Venclexta as a first-line option that improved progression-free survival compared with standard chemo in adults with CLL or SLL.

Dr. Gwen Nichols explains how Orca‑T may reduce graft-versus-host disease and impact treatment decisions for certain patients with blood cancers.

Annamycin plus cytarabine achieved a 40% preliminary remission rate in relapsed AML, including patients who previously received Venclexta-based therapy.

A patient with cancer reflects on participating in a clinical study and how community and creativity helped ease chemo brain symptoms.

FDA approves Filkri, a biosimilar that helps reduce infection risk and speed white blood cell recovery during chemotherapy and other treatments.

The FDA approved a larger nelarabine vial to improve dosing flexibility and simplify treatment for adult and pediatric patients with T-ALL and T-LBL.

The FDA granted orphan drug designation to CTD402 for relapsed or refractory T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma.

The allogeneic CAR-T therapy aims to expand urgently needed options for children and adults with aggressive T-cell blood cancers.

A chronic myeloid leukemia diagnosis can be daunting, but its management is one of modern oncology’s greatest success stories.

For people who are expected or required to be compassionate in their everyday life or work they should start by training in compassion.

A new combination of Blincyto and Iclusig provided improved results and stronger responses for patients with Philadelphia chromosome-positive ALL compared with traditional chemotherapy.

Among fit patients with acute myeloid leukemia, azacitidine plus Venclexta was shown to be superior to intensive chemotherapy.

Race has been identified as an independent prognostic factor in patients with AML receiving intensive chemotherapy.

Venclexta regimens showed comparable progression-free survival versus continuous Imbruvica.